{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:52:50Z","timestamp":1791035570114,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI23\/00164"],"award-info":[{"award-number":["PI23\/00164"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.medcli.2026.107574","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:20:26Z","timestamp":1787372426000},"page":"107574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapies in hereditary hemorrhagic telangiectasia: Current evidence and emerging targets"],"prefix":"10.1016","volume":"166","author":[{"given":"Sabela","family":"Casta\u00f1eda-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ordieres-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eide Diana","family":"Alves-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Riera-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2026.107574_bib0300","article-title":"Global prevalence of hereditary hemorrhagic telangiectasia-associated variants estimated by analysis of large-scale genomic databases","volume":"27","author":"Gaetani","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2026.107574_bib0305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu\u2013Osler\u2013Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.medcli.2026.107574_bib0310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jmg.2005.035451","article-title":"Genotype\u2013phenotype relationship in hereditary haemorrhagic telangiectasia","volume":"43","author":"Letteboer","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.medcli.2026.107574_bib0315","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajmg.a.31101","article-title":"Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations","volume":"140","author":"Bayrak-Toydemir","year":"2006","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.medcli.2026.107574_bib0320","doi-asserted-by":"crossref","first-page":"e176379","DOI":"10.1172\/JCI176379","article-title":"Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances","volume":"134","author":"Al Tabosh","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.medcli.2026.107574_bib0325","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan6831","article-title":"Inactivating mutations in Drosha mediate vascular abnormalities similar to hereditary hemorrhagic telangiectasia","volume":"11","author":"Jiang","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.medcli.2026.107574_bib0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2023.08.024","article-title":"New genetic drivers in hemorrhagic hereditary telangiectasia","volume":"119","author":"Cerd\u00e0","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1358863X231151731","article-title":"Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler\u2013Weber\u2013Rendu disease)","volume":"28","author":"Alkhalid","year":"2023","journal-title":"Vasc Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0340","series-title":"GeneReviews\u00ae [Internet]","article-title":"Hereditary hemorrhagic telangiectasia","author":"McDonald","year":"2000"},{"key":"10.1016\/j.medcli.2026.107574_bib0345","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rce.2018.07.002","volume":"218","author":"Riera-Mestre","year":"2018","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.medcli.2026.107574_bib0350","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/ajmg.a.32243","article-title":"Genotype\u2013phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia","volume":"146A","author":"Letteboer","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.medcli.2026.107574_bib0355","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","article-title":"Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study","volume":"84","author":"Donaldson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.medcli.2026.107574_bib0360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.medcli.2026.107574_bib0365","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00405-024-09177-9","article-title":"Efficacy of bevacizumab in hereditary hemorrhagic telangiectasia: a systematic review and network meta-analysis","volume":"282","author":"Taha","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.medcli.2026.107574_bib0370","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH06-07-0373","article-title":"Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1\/endoglin pathway in endothelial cells","volume":"97","author":"Fernandez-LA","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2026.107574_bib0375","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2026.107574_bib0380","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11882-023-01116-8","article-title":"Treatments of epistaxis in hereditary hemorrhagic telangiectasia: systematic review and network meta-analysis","volume":"23","author":"Chitsuthipakorn","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.medcli.2026.107574_bib0385","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid \u2013 a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2026.107574_bib0390","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0395","series-title":"A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) [Internet]. ClinicalTrials.gov","year":"2024"},{"key":"10.1016\/j.medcli.2026.107574_bib0400","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","article-title":"Bevacizumab in hereditary hemorrhagic telangiectasia","volume":"360","author":"Bose","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0405","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2026.107574_bib0410","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241300828","article-title":"BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study","volume":"16","author":"Dupuis-Girod","year":"2025","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.medcli.2026.107574_bib0415","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.medcli.2026.107574_bib0420","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/alr.23566","article-title":"The effect of systemic bevacizumab on epistaxis-related outcomes in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis","volume":"15","author":"Li","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.medcli.2026.107574_bib0425","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medcli.2026.107574_bib0430","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0435","article-title":"Pomalidomide for hereditary hemorrhagic telangiectasia: After Trial Longitudinal Assessment Study (PATH-HHT ATLAS)","volume":"9","author":"Zhang","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2026.107574_bib0440","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2141.2009.07730.x","article-title":"Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?","volume":"146","author":"Bowcock","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2026.107574_bib0445","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1710376","article-title":"Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang\/Tie, and inflammatory pathways","volume":"16","author":"Zong","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2026.107574_bib0450","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","article-title":"Aflibercept","volume":"11","author":"Stewart","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.medcli.2026.107574_bib0455","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3390\/medicina59091533","article-title":"Aflibercept for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: a case report","volume":"59","author":"Villanueva","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.medcli.2026.107574_bib0460","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1002\/ajh.25563","article-title":"Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: a prospective case series","volume":"94","author":"Kroon","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2026.107574_bib0465","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"10","author":"Torres-Iglesias","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.medcli.2026.107574_bib0470","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10456-024-09961-5","article-title":"Genetic and pharmacological targeting of mTORC1 in mouse models of arteriovenous malformation expose non-cell autonomous signalling in HHT","volume":"28","author":"Queiro-Palou","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.medcli.2026.107574_bib0475","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.3390\/jcm11195624","article-title":"Perioperative complications and long-term follow-up of liver transplantation in hemorrhagic hereditary telangiectasia: report of three cases and systematic review","volume":"24","author":"Riera-Mestre","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0480","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/ATVBAHA.118.310760","article-title":"ALK1 loss results in vascular hyperplasia in mice and humans through PI3K activation","volume":"38","author":"Alsina-Sanch\u00eds","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.medcli.2026.107574_bib0485","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/cells8090971","article-title":"PI3K (phosphatidylinositol 3-kinase) activation and endothelial cell proliferation in patients with hemorrhagic hereditary telangiectasia type 1","volume":"24","author":"Iriarte","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.medcli.2026.107574_bib0490","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.medcli.2023.06.021","article-title":"Hereditary hemorrhagic telangiectasia relapse in liver allograft","volume":"27","author":"Riera-Mestre","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2026.107574_bib0495","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.30870","article-title":"Letter to the Editor: mTOR-inhibitor-based immunosuppression following liver transplantation for hereditary hemorrhagic telangiectasia","volume":"71","author":"Castellote","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medcli.2026.107574_bib0500","unstructured":"ClinicalTrials.gov. Sirolimus for nosebleeds in hereditary hemorrhagic telangiectasia (HHT): a phase II pilot study (NCT05269849) [Internet]. Bethesda, MD: National Library of Medicine (US); 2022. Accessed 23.12.25."},{"key":"10.1016\/j.medcli.2026.107574_bib0505","unstructured":"ClinicalTrials.gov. Efficacy of sirolimus in severe arteriovenous malformations (AVM-RAPA) (NCT02042326) [Internet]. Bethesda, MD: National Library of Medicine (US); 2014. Accessed 23.12.25."},{"key":"10.1016\/j.medcli.2026.107574_bib0510","unstructured":"ClinicalTrials.gov. Sirolimus in treating patients with complicated vascular anomalies (NCT00975819) [Internet]. Bethesda, MD: National Library of Medicine (US); 2009. Accessed 23.12.25."},{"key":"10.1016\/j.medcli.2026.107574_bib0515","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.110.067447","article-title":"Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-\u03b21 signaling in endothelial cells","volume":"79","author":"Albi\u00f1ana","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.medcli.2026.107574_bib0520","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.3390\/jcm11185280","article-title":"Efficacy and safety of tacrolimus as treatment for bleeding caused by hereditary hemorrhagic telangiectasia: an open-label, pilot study","volume":"11","author":"Hessels","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2026.107574_bib0525","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"10.1016\/j.medcli.2026.107574_bib0530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10456-024-09962-4","article-title":"Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial","volume":"28","author":"Hermann","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.medcli.2026.107574_bib0535","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMoa2504411","article-title":"Engasertib versus placebo for bleeding in hereditary hemorrhagic telangiectasia","volume":"393","author":"Al-Samkari","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.medcli.2026.107574_bib0540","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2024-206244","article-title":"A randomized, placebo-controlled, multicenter proof-of-concept study to assess the safety and efficacy of the novel allosteric AKT inhibitor, VAD044, in adults with hereditary hemorrhagic telangiectasia","volume":"144","author":"Al-Samkari","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2026.107574_bib0545","unstructured":"ClinicalTrials.gov. A trial of TER-1754 in patients with hereditary hemorrhagic telangiectasia (NCT07255846) [Internet]. ClinicalTrials.gov. 2025. Accessed 15.2.26."},{"key":"10.1016\/j.medcli.2026.107574_bib0550","unstructured":"ClinicalTrials.gov. Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) (NCT07601425). Accessed 9.6.26."},{"key":"10.1016\/j.medcli.2026.107574_bib0555","article-title":"ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia","author":"Qutaina","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.medcli.2026.107574_bib0560","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/CIRCULATIONAHA.122.062952","article-title":"Induced endothelial cell cycle arrest prevents arteriovenous malformations in hereditary hemorrhagic telangiectasia","volume":"149","author":"Genet","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2026.107574_bib0565","unstructured":"Tectonic Therapeutic. Press release. February 11, 2026. Accessed 15.2.26."},{"key":"10.1016\/j.medcli.2026.107574_bib0570","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/03009734.2018.1483452","article-title":"Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital","volume":"123","author":"Karlsson","year":"2018","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.medcli.2026.107574_bib0575","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians","volume":"48","author":"Al-Samkari","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medcli.2026.107574_bib0580","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.2023021765","article-title":"treat bleeding in hereditary hemorrhagic telangiectasia","volume":"144","author":"Al-Samkari","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2026.107574_bib0585","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049567","article-title":"Therapeutic targeting of vascular malformation in a zebrafish model of hereditary haemorrhagic telangiectasia","volume":"16","author":"Snodgrass","year":"2023","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.medcli.2026.107574_bib0590","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ajh.70011","article-title":"Standardization of terminology, definitions, and outcome criteria for bleeding in hereditary hemorrhagic telangiectasia: international consensus report","volume":"100","author":"Al-Samkari","year":"2025","journal-title":"Am J Hematol"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:57:29Z","timestamp":1791032249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775326002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0025775326002241"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107574","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapies in hereditary hemorrhagic telangiectasia: Current evidence and emerging targets","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107574"}}